Search
Cancer Paid Clinical Trials in Indiana
A listing of 210 Cancer clinical trials in Indiana actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
49 - 60 of 210
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Indiana currently has 210 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Indianapolis, South Bend, Fort Wayne and Evansville.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Irritability Associated with Autism (Children and Adolescents) Study
Recruiting
Become part of a clinical trial today and play a role in driving medical research forward, aiding in the discovery of groundbreaking therapies. Get rewarded for your time with monetary compensation and enjoy access to medical treatment at no charge.
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.
The study drugs involved in this study are:
A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO)
Hormonal (endocrine) Treatment
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Indiana University Health Schwarz Cancer Center, Indianapolis, Indiana +2 locations
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Recruiting
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Indiana U Simon Cancer Center, Indianapolis, Indiana
Conditions: Small Cell Lung Cancer (SCLC)
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Recruiting
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Indiana University Health Neuroscience Center, Indianapolis, Indiana
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Reid Health, Richmond, Indiana
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Recruiting
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Urology of Indiana, Greenwood, Indiana +1 locations
Conditions: Metastatic Castrate-sensitive Prostate Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Recruiting
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Urology of Indiana, Carmel, Indiana +1 locations
Conditions: Bladder Cancer
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
Recruiting
The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).
Gender:
All
Ages:
40 years and above
Trial Updated:
04/22/2024
Locations: Deaconess Clinic, Inc., Evansville, Indiana +2 locations
Conditions: Colorectal Cancer
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer, Indianapolis, Indiana
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Metastatic Urothelial Cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Research Site, Goshen, Indiana
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2 Study of DKN-01 in Colorectal Cancer
Recruiting
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2024
Locations: Hematology Oncology of Indiana, PC - Indianapolis, Indianapolis, Indiana
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
Recruiting
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Indiana University (IU), Indianapolis, Indiana
Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
49 - 60 of 210